share_log

Palisade Bio to Participate in the Virtual Investor Closing Bell Series

Palisade Bio to Participate in the Virtual Investor Closing Bell Series

Palisade Bio將參加虛擬投資者收盤鍾系列活動
Palisade Bio ·  06/24 00:00

Live video webcast on Wednesday, June 26th at 4:00 PM ET

6月26日星期三將進行現場視頻網絡直播th美國東部時間下午4:00

Carlsbad, CA, June 24, 2024 — Palisade Bio, Inc. (Nasdaq: PALI) ("Palisade" or the "Company"), biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it will participate in the Virtual Investor Closing Bell Series on Wednesday, June 26, 2024 at 4:00 PM ET.

加州卡爾斯巴德,2024年6月24日—Palisade Bio公司。(納斯達克:PALI)(“Palisade”或“公司”),一家專注於開發和推進針對自身免疫性、炎性和纖維化疾病的新型治療方法的生物製藥公司,今天宣佈將參加“虛擬投資者收盤鍾系列活動”,時間爲2024年6月26日星期三下午4:00 ET。於2024年6月26日星期三美國東部時間下午4點進行。

As part of the event, J.D. Finley, Chief Executive Officer, and Dr. Mitch Jones, Chief Medical Officer, of Palisade Bio will provide a corporate overview and business outlook. In addition to the moderated discussion, investors and interested parties will have the opportunity to submit questions live during the event. The Company will answer as many questions as possible in the time allowed.

作爲活動的一部分,Palisade Bio 的首席執行官 J.D. Finley 和首席醫療官 Dr. Mitch Jones 將提供公司概況和業務前景。除了主持的討論,投資者和有興趣的各方還將有機會在活動期間直播提交問題。公司將在允許的時間內回答儘可能多的問題。

A live video webcast of the presentation will be available on the Events page of the Investors section of the Company's website (www.palisadebio.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.

About Palisade Bio

關於Palisade Bio

Palisade Bio is a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to www.palisadebio.com.

Palisade Bio是一家生物製藥公司,專注於開發和推進新型治療自身免疫、炎症和纖維化疾病的藥物。該公司相信,通過使用其新型治療方法,將改變治療局面。有關詳細信息,請訪問公司網站www.palisadebio.com.

Investor Relations Contact
JTC Team, LLC
Jenene Thomas
833-475-8247
PALI@jtcir.com

投資者關係聯繫人
JTC團隊有限責任公司
Jenene Thomas
833-475-8247
PALI@jtcir.com

Source: Palisade Bio

資料來源:Palisade Bio

Primary Logo

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論